9:17 PM
 | 
Jul 31, 2009
 |  BC Extra  |  Top Story

FDA to re-inspect Genzyme plant

Genzyme Corp. (NASDAQ:GENZ) fell $4.36 to $51.89 on Friday after announcing that the company's Allston, Mass., manufacturing facility did not pass a May FDA inspection. The agency will now re-inspect the facility. Last week, the company had said it passed the...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >